2018. Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma. SKIN The Journal of Cutaneous Medicine. 2, (Dec. 2018), S77. DOI:https://doi.org/10.25251/skin.2.supp.77.